ARA-290 Guide & Dosage Chart

What is ARA-290?

ARA-290 — also called Cibinetide — is a small synthetic peptide derived from erythropoietin (EPO), the hormone your body uses to make red blood cells. Scientists took a tiny slice of EPO's structure and engineered it to keep EPO's tissue-protecting and anti-inflammatory powers while removing its red-blood-cell-stimulating effect.^[2] That matters a lot in research: full EPO can dangerously thicken the blood, but ARA-290 sidesteps that risk.^[5] It is classified as a research-use-only compound and is not approved as a medicine.

How ARA-290 Works

Think of your body's immune and pain systems as two neighbors who share a fence. ARA-290 works at that fence — a molecular receptor called the Innate Repair Receptor (IRR), which is made of two proteins (EPOR and CD131) joined together. When ARA-290 binds the IRR, it tells immune cells to tone down inflammation and tells damaged nerve and tissue cells to start repairing themselves.^[6]

There's a second mechanism too. Research found that ARA-290 can directly block a pain-sensing channel called TRPV1 — the same channel that capsaicin (hot pepper) activates. By quieting TRPV1, ARA-290 may reduce the exaggerated pain signals that fire in neuropathic pain conditions.^[3] In short: it calms the immune alarm bells and turns down the volume on pain nerves at the same time.

What the Research Shows

Neuropathic Pain in Sarcoidosis

Sarcoidosis is an inflammatory disease that can destroy the tiny nerve fibers running through your skin, causing burning pain and numbness. Two Phase II clinical trials tested ARA-290 in these patients. Results showed significant reductions in pain scores on validated questionnaires, measurable regrowth of corneal nerve fibers, improved sensory thresholds, and better quality of life.^[2] The effects were described as long-lasting, which led researchers to wonder whether ARA-290 might actually modify the disease rather than just mask symptoms.^[2]

Pain Relief via TRPV1 Blocking

Lab studies using calcium imaging and behavioral tests showed ARA-290 could specifically inhibit TRPV1 channel activity and reduce mechanical hypersensitivity caused by capsaicin.^[3] This suggests the peptide may act as a novel TRPV1 antagonist — a finding that broadens our understanding of how the immune and pain systems talk to each other.^[3]

Diabetic Neuropathy

Diabetic neuropathy affects up to 50% of people with long-standing diabetes, yet very few treatments address the underlying nerve damage rather than just the pain.^[4] ARA-290 (Cibinetide) has been identified as one of the more promising investigational candidates in this space, with researchers highlighting it in systematic reviews of agents with demonstrated safety and early signs of benefit.^[4]

Inflammatory Bowel Disease

In a mouse model of colitis, both EPO and Cibinetide improved weight, survival, and tissue integrity. Cibinetide reduced the flood of inflammatory immune cells into gut tissue and lowered levels of pro-inflammatory molecules. The researchers traced this back to the IRR receptor and a signaling pathway that dials down NF-κB — a master switch for inflammation.^[6]

Alzheimer's-Like Pathology

In mice engineered to develop Alzheimer's-like plaques, early treatment with ARA-290 slowed the buildup of amyloid-β and improved cognitive function. It did this by boosting a specific type of patrolling monocyte (Ly6C^Low) that clears amyloid from blood vessels in the brain.^[5] Importantly, this benefit disappeared when treatment started late in the disease — suggesting timing matters.^[5]

What ARA-290 Is Being Studied For

• Sarcoidosis-associated small fiber neuropathy and neuropathic pain^[2]
• Diabetic neuropathy and wound healing^[4]
• Islet transplantation protection (preserving transplanted insulin-producing cells)
• Inflammatory bowel disease / colitis^[6]
• Alzheimer's disease pathology (early-stage preclinical models)^[5]
• General tissue protection and pain relief via TRPV1 modulation^[3]

How ARA-290 Is Dosed in Research

Doses in published studies vary widely depending on the model and the goal. Preclinical mouse work has used doses as low as 30 mcg/day for wound healing models, while human Phase II trials for sarcoidosis-related neuropathy tested 1 mg, 4 mg, and 8 mg daily over 28 days, with the 4 mg daily protocol emerging as the apparent optimal dose.^[2] Islet transplant protocols used a different schedule entirely — multiple doses timed around the surgical procedure. Because the right dose depends entirely on the research context, please refer to the dosage chart on this page for the full breakdown, and use the calculator to work out volumes for your specific reconstitution. These figures are for research reference only and do not constitute medical advice.

Mixing and Storing ARA-290

ARA-290 is typically supplied as a lyophilized (freeze-dried) powder in a sealed vial. To reconstitute it, researchers commonly add bacteriostatic water or sterile saline slowly down the side of the vial — never shake it, as this can break down the peptide structure. Gently swirl until the powder fully dissolves. Once mixed, the solution should be stored in a refrigerator (2–8 °C) and used within a few weeks; for longer storage, keep the unmixed powder frozen at –20 °C and away from light. Always label your vial with the date of reconstitution. As with all research peptides, handle with appropriate lab precautions and discard any solution that looks cloudy or discolored.

Sources

1. Editorial. — Molecular medicine (Cambridge, Mass.), 2013. PMID 24178588.
2. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. — Expert opinion on investigational drugs, 2014. PMID 24555851.
3. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. — Peptides, 2016. PMID 26774587.
4. The time to develop treatments for diabetic neuropathy. — Expert opinion on investigational drugs, 2021. PMID 33423557.
5. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. — Brain, behavior, and immunity, 2022. PMID 34343617.
6. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. — Scientific reports, 2017. PMID 29026145.